Royalty Pharma PLC
F:RPD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Royalty Pharma PLC
F:RPD
|
US |
|
S
|
SP Group A/S
F:1PU2
|
DK |
|
IRIDEX Corp
NASDAQ:IRIX
|
US |
|
A
|
Amada Co Ltd
XMUN:AA2
|
JP |
|
I
|
International Game Technology PLC
DUS:7IG
|
UK |
|
Eastern Bankshares Inc
F:EB0
|
US |
|
C
|
Corbus Pharmaceuticals Holdings Inc
F:337
|
US |
|
Nedap NV
F:NE3
|
NL |
|
Vusiongroup SA
PAR:VU
|
FR |
|
Fuchs Se
F:FPE3
|
DE |
|
Latham Group Inc
NASDAQ:SWIM
|
US |
|
T
|
Takeda Pharmaceutical Co Ltd
SWB:TKDA
|
JP |
|
S
|
Stratasys Ltd
F:SCY
|
US |
Dividends
Dividend Yield
Royalty Pharma PLC
| Current Yield | |
| Min Yield | |
| Max Yield | |
| Average Yield | |
| Median Yield |
Dividend Per Share
Royalty Pharma PLC
RPD have increased by 122%.
Payout Ratio
Royalty Pharma PLC
Peers Comparison
Dividends
Shareholder Yield
Current shareholder yield for RPD is
hidden
.
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
RPD Price
Royalty Pharma PLC
| Average Annual Return | -3.49% |
| Standard Deviation of Annual Returns | 18.82% |
| Max Drawdown | -46% |
| Market Capitalization | 34B EUR |
| Shares Outstanding | 597 440 000 |
| Percentage of Shares Shorted |
N/A
|
